title: Long Coronary Lesions Treated With Thin Strut Bioresorbable Polymer Drug Eluting Stent: Experience From Multicentre Randomized CENTURY II Study.
abstract: OBJECTIVE
  To assess performance of new, bioresorbable polymer sirolimus-eluting stent (BP-SES), in patients with long coronary lesions (LL) and to compare it to permanent polymer everolimus-eluting stent (PP-EES).
  
  
  BACKGROUND
  LL have been associated with worse clinical outcomes in percutaneous coronary interventions (PCI). The impact of lesion length on the outcomes of drug eluting stent (DES) implantations is not as clear.
  
  
  METHODS
  In the frame of a randomized, multicentre CENTURY II study, out of 1119 patients enrolled, 182 patients had LL (defined as ≥25 mm), and were assigned randomly to treatment with BP-SES (101) or PP-EES (81). Primary endpoint was target lesion failure (TLF, composite of cardiac death, target vessel related myocardial infarction [MI], and target lesion revascularization [TLR]) at 9 months. All data were 100% monitored and adverse events were adjudicated by an independent clinical event committee.
  
  
  RESULTS
  The baseline patient and lesion characteristics were similar in the 2 study arms. At 9-months, the rates of cardiac death (2.0% vs 1.2%; P = 0.70), MI (3.0% vs 4.9%; P = 0.49) and clinically driven TLR (2.0% vs 3.7%; P = 0.48) and TLF (6.9% vs 8.6%; P = 0.67) were similar for BP-SES and PP-EES, respectively. There was no stent thrombosis (ST) in BP-SES group up to 9 months, while 1 case (1.2%) of ST was recorded in PP-EES group (P = 0.44).
  
  
  CONCLUSIONS
  Patients with LL showed similar clinical outcomes when treated with Ultimaster BP-SES and Xience PP-EES.
authors: Department of Cardiology, University of Medical Sciences, Poznan, Poland.
authors: Maciej
authors: M
authors: Lesiak
authors: Department of Cardiology, University of Medical Sciences, Poznan, Poland.
authors: Aleksander
authors: A
authors: Araszkiewicz
authors: Department of Cardiology, University of Medical Sciences, Poznan, Poland.
authors: Stefan
authors: S
authors: Grajek
authors: Cardiac Cath Lab and Interventional Cardiology Unit EMO GVM Centro Cuore, Columbus and San Raffaele Hospital, Milan, Italy.
authors: Antonio
authors: A
authors: Colombo
authors: Department of Cardiology, CHU de Charleroi, Charleroi, Belgium.
authors: Jacques
authors: J
authors: Lalmand
authors: Department of Cardiology, Roskilde University Hospital, Roskilde, Denmark.
authors: Steen
authors: S
authors: Carstensen
authors: Department of Cardiology, Kanto Rosai Hospital, Kawasaki, Japan.
authors: Atsuo
authors: A
authors: Namiki
authors: Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
authors: Tetsuya
authors: T
authors: Tobaru
authors: Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
authors: Béla
authors: B
authors: Merkely
authors: Department of Interventional Cardiology, University Hospital La Paz, Madrid, Spain.
authors: Raul
authors: R
authors: Moreno
authors: Cardiovascular Center Aalst, OLV Hospital, Aalst, Belgium.|Departement of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy.
authors: Emanuele
authors: E
authors: Barbato
authors: Cardiovascular Center Aalst, OLV Hospital, Aalst, Belgium.
authors: William
authors: W
authors: Wijns
authors: Department of Cardiology and Catheterization Laboratory, Shonan Kamakura General Hospital, Kamakura, Japan.
authors: Shigeru
authors: S
authors: Saito
mesh_terms: D020341:Absorbable Implants; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D023921:Coronary Stenosis / Q000175:diagnosis / Q000601:surgery; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods; D011108:Polymers; D011183:Postoperative Complications / Q000453:epidemiology*; D011474:Prosthesis Design; D012307:Risk Factors; D012720:Severity of Illness Index; D020123:Sirolimus / Q000494:pharmacology*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011108:Polymers; D000068338:Everolimus; D020123:Sirolimus